[CAS NO. 31656-62-9] Benzamide- 15 N
PRODUCTS SPECIFICATIONS [31656-62-9]
DESCRIPTION [31656-62-9]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 122.13 |
| Molecular Formula | C7H715NO |
| SMILES | O=C([15NH2])C1=CC=CC=C1 |
Summary
In Vitro
Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : 100 mg/mL ( 818.80 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 8.1880 mL | 40.9400 mL | 81.8800 mL |
| 5 mM | 1.6376 mL | 8.1880 mL | 16.3760 mL |
| 10 mM | 0.8188 mL | 4.0940 mL | 8.1880 mL |
References
- [1] Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.
- [2] Cosi C, et al. Benzamide, an inhibitor of poly(ADP-ribose) polymerase, attenuates methamphetamine-induced dopamine neurotoxicity in the C57B1/6N mouse. Brain Res. 1996;735(2):343-348.